Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 4/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2720266 | 1.00 | EPHX1 (0.57) | EPHX1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL22937469 | 0.82 | EPHX1 (0.50) | EPHX1NPC1RAB9AALOX5 | |
| SCHEMBL4597385 | 0.82 | MEN1 (0.57) | EPHX1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL14032489 | 0.82 | TAAR1 (0.59) | EPHX1SMN1; SMN2 | |
| SCHEMBL23643109 | 0.82 | EPHX1 (0.50) | EPHX1ACACBALOX5SMN1; SMN2 | |
| SCHEMBL23643108 | 0.82 | EPHX1 (0.50) | EPHX1ALOX5SMN1; SMN2 | |
| SCHEMBL22235331 | 0.82 | KMT2A (0.53) | EPHX1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL21129085 | 0.82 | MEN1 (0.57) | EPHX1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL22593510 | 0.82 | EPHX1 (0.50) | EPHX1NPC1RAB9AACACBALOX5 | |
| SCHEMBL934530 | 0.82 | TAAR1 (0.59) | EPHX1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIF5B, KIF2C, PLK1 | EPHX1 2410/4885KMT2A 1501/4885MEN1 1302/4885 |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | KIF5B, KIF2C, PLK1 | EPHX1 2286/4885KMT2A 1491/4885MEN1 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.